Wouter Verhoeven, Dualyx CEO

Bel­gian biotech Du­a­lyx en­ters Treg field with $44M for 2024 clin­i­cal en­try

A young Bel­gian biotech aims to en­ter the clin­ic next year with a new Treg for au­toim­mune dis­eases, and now has

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.